Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 14/20 | 0.47 |
| ▸ | PTPRA | P18433 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | PTPN22 | Q9Y2R2 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1731192 | 1.00 | PTPN1 (0.47) | PTPN1PTPRABRD4PLGPRSS1 | |
| SCHEMBL5893307 | 0.92 | PTPN1 (0.53) | PTPN1PTPRAAKT1 | |
| SCHEMBL1732320 | 0.92 | PTPN1 (0.47) | PTPN1PTPRABRD4PLGPRSS1 | |
| SCHEMBL5893907 | 0.91 | PTPN1 (0.55) | PTPN1PTPRAAKT1 | |
| SCHEMBL6141344 | 0.90 | PTPN1 (0.48) | PTPN1PTPRAPLGPRSS1PRSS2 | |
| SCHEMBL1731676 | 0.87 | ITGB3 (0.47) | PTPN1 | |
| SCHEMBL1731679 | 0.87 | ITGB3 (0.47) | PTPN1 | |
| SCHEMBL1732762 | 0.87 | PTPN1 (0.54) | PTPN1PTPRAPLGPRSS1PRSS2 | |
| SCHEMBL1732761 | 0.87 | PTPN1 (0.54) | PTPN1PTPRAPLGPRSS1PRSS2 | |
| SCHEMBL1732843 | 0.85 | PTPN1 (0.49) | PTPN1PTPRABRD4PLGPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | COPPOLA GARY MARK | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | PTPRS, PTPA, PTPMT1 | PTPN1 9/4885PTPRA 19/4885BRD4 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.